Jim Simons Unicycive Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.4 - $1.46 $23,864 - $87,103	-59,660 Reduced 64.25%	33,200 $16,000
Q1 2024 May 13, 2024	BUY	$0.83 - $1.79 $48,775 - $105,191	58,766 Added 172.36%	92,860 $128,000
Q4 2023 Feb 13, 2024	BUY	$0.49 - $0.92 $16,706 - $31,366	34,094 New	34,094 $30,000
Q3 2022 Nov 14, 2022	BUY	$0.57 - $0.9 $1,083 - $1,710	1,900 Added 17.27%	12,900 $8,000
Q2 2022 Aug 12, 2022	BUY	$0.7 - $1.33 $7,699 - $14,630	11,000 New	11,000 $9,000

46.8M

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $10.5M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.